Perspective. In the article “Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART” by Edward A. Berger, Bernard Moss, and Ira Pastan, which appeared in number 20, September 29, 1998, of Proc. Natl. Acad. Sci. USA (95, 11511–11513), it should be noted that the authors are co-inventors on patents covering the use of recombinant Pseudomonas exotoxin. The patents state that “A chimeric gene directing the synthesis of hybrid recombinant fusion protein in a suitable expression vector has been constructed. The fusion protein possesses the property of selective cytotoxicity against specific virus-infected cells. A CD4(178)-PE40 hybrid fusion protein has been made for selectively killing HIV-infected cells.” The U.S. Patent Numbers are 5587455, 5428143, and 5206353.